References
- Agostoni A, Aygoren-Pursun E, Binkley KE, et al., et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 Suppl):S51–131. Epub 2004/09/10
- Kalmár L, Hegedüs T, Farkas H, et al. HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat. 2005;25(1):1–5.
- Rosen FS, Pensky J, Donaldson V, et al. Hereditary Angioneurotic Edema: Two Genetic Variants. Science. 1965;148(3672):957–958.
- Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol. 2010;47(13):2161–2169.
- Nussberger J, Cugno M, Cicardi M, et al. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104(6):1321–1322.
- Kaplan AP. Bradykinin and the pathogenesis of hereditary angioedema. World Allergy Organ J. 2011;4(4):73–75.
- Farkas H. Orphan drugs for the treatment of hereditary angioedema. Expert Opinion on Orphan Drugs. 2013;1(2):141–156.
- Cicardi M, Aberer W, Banerji A, et al., et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–16.
- Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–274.
- Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101(3):619–627.
- Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–697.
- Bygum A, Aygören-Pürsün E, Beusterien K, et al., et al. Burden of illness in hereditary angioedema: A conceptual model. Acta Derm Venereol. 2015;95(6):706–710.
- Cicardi M, Bork K, Caballero T, et al., et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147–57.
- Bork K. Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency. Expert Rev Clin Immunol. 2011;7(6):723–733.
- Gompels MM, Lock RJ. Cinryze (C1-inhibitor) for the treatment of hereditary angioedema. Expert Rev Clin Immunol. 2011;7(5):569–573.
- Li HH, Moldovan D, Bernstein JA, et al., et al. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(3):417–423.
- Duffey H, Firszt R. Management of acute attacks of hereditary angioedema: role of ecallantide. J Blood Med. 2015;6:115–123.
- Ghazi A, Grant JA. Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics. 2013;7:103–113.
- Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med. 1972;287(9):452–454.
- van Geffen M, Cugno M, Lap P, et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol. 2012;167(3):472–478.
- Gelfand JA, Sherins RJ, Alling DW, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976;295(26):1444–1448.
- Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol. 2008;100(2):153–161.
- Späth PJ, Wüthrich B, Bütler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema–evidence of a functionally critical level of C1-inhibitor concentration. Complement. 1984;1(3):147–159.
- Zuraw BL, Busse PJ, White M, et al., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513–522.
- Berinert®, C1 Esterase Inhibitor (Human), FULL PRESCRIBING INFORMATION. Clean Package Insert (cf45d7)_Version 35.0 Available at:www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM186268.pdf.
- Berinert 500 IU. Last Updated on electronic Medicines Compendium (eMC) 02-Sep-2015. Available at: www.medicines.org.uk/emc/medicine/21650.
- CINRYZE® (C1 Esterase Inhibitor [Human].FULL PRESCRIBING INFORMATION. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM129918.pdf.
- ANNEX I. Summary of product characteristics.Cinryze 500 Units powder and solvent for solution for injection. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001207/WC500108895.pdf.
- CHMP assessment report. Ruconest European Medicines Agency, 2010. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001223/WC500098546.pdf.
- Ruconest (C1 esterase inhibitor [recombinant]). FULL PRESCRIBING INFORMATION. Available at: www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM405634.pdf.
- Farrell C, Hayes S, Relan A, et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol. 2013;76(6):897–907.
- Choi G, Soeters MR, Farkas H, et al., et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion. 2007;47(6):1028–1032.
- Zuraw B, Cicardi M, Levy RJ, et al., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821–7 e14.
- Riedl MA, Bernstein JA, Li H, et al., et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163–9 e1.
- Moldovan D, Reshef A, Fabiani J, et al., et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy. 2012;42(6):929–35.
- Riedl MA, Levy RJ, Suez D, et al., et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol. 2013;110(4):295–9.
- KALBITOR® (ecallantide). FULL PRESCRIBING INFORMATION. Available at: www.kalbitor.com/hcp/rems/pdf/KalbitorFullPrescribingInformation.pdf
- ANNEX I. Summary of product characteristics. Firazyr 30 mg solution for injection in pre-filled syringe. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000899/WC500022966.pdf.
- FIRAZYR® (icatibant). FULL PRESCRIBING INFORMATION. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf.
- Eldering E, Nuijens JH, Hack CE. Expression of functional human C1 inhibitor in COS cells. J Biol Chem. 1988;263(24):11776–11779.
- Eldering E, Huijbregts CC, Lubbers YT, et al. Characterization of recombinant C1 inhibitor P1 variants. J Biol Chem. 1992;267(10):7013–7020.
- Lamark T, Ingebrigtsen M, Bjørnstad C, et al. Expression of active human C1 inhibitor serpin domain in Escherichia coli. Protein Expr Purif. 2001;22(2):349–358.
- Wolff MW, Zhang F, Roberg JJ, et al., et al. Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization. Protein Expr Purif. 2001;22(3):414–421.
- Relan A, Bakhtiari K, van Amersfoort ES, et al. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema. BioDrugs. 2012;26(1):43–52.
- van Veen HA, Koiter J, Vogelezang CJ, et al., et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol. 2012;162(2–3):319–326.
- Ruconest. European Medicines Agency, 2015. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001223/WC500098544.pdf.
- Perkins SJ. Three-dimensional structure and molecular modelling of C1- inhibitor. Behring Inst Mitt. 1993;93:63–80.
- Koles K, van Berkel PH, Pieper FR, et al., et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology. 2004;14(1):51–64.
- Koles K, van Berkel PH, Mannesse ML, et al. Influence of lactation parameters on the N-glycosylation of recombinant human C1 inhibitor isolated from the milk of transgenic rabbits. Glycobiology. 2004;14(11):979–986.
- van Doorn MB, Burggraaf J, van Dam T, et al., et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005;116(4):876–883.
- Moldovan D, Bernstein JA, Cicardi M. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy. 2015;7(7):739–752.
- Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion. 2010;50(2):354–360.
- Bernstein JA, Ritchie B, Levy RJ, et al., et al. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010;105(2):149–154.
- Kusuma A, Relan A, Knulst AC, et al., et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med. 2012;125(9):937 e17–24.
- Suez D, Moldovan D, Baker JW, et al., et al. Efficacy of recombinant human C1 inhibitor treatment for abdominal attacks of hereditary angioedema. J Allergy Clin Immunol. 2012;129(2):Ab222–Ab.
- Riedl M, Cicardi M. Efficacy of recombinant human C1 inhibitor for laryngeal attacks of hereditary angioedema. Special issue: abstracts from the European Academy of Allergy and Clinical Immunology Congress, 6–10 June 2015, Barcelona (Spain).Poster Session Group II – Red TPS 20. Allergy. 2015;70:409–506.
- Levy R, Moldovan D, Hack CE, et al. Efficacy of recombinant human C1 inhibitor treatment for acute upper airway attacks in hereditary angioedema patients. J Angioedema. 2011;1(1):30.
- Toubi E, Baker J, Moldovan D, et al. Safety and efficacy evaluation of rhC1INH for the treatment of hereditary angioedema attacks in adolescent patients. Allergy. 2012;67:199.
- Reshef A, Zanichelli A, Longhurst H, et al. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy. 2015;70(5):506–513.
- Hack CE, Mannesse M, Baboeram A, et al. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs. 2012;26(5):303–13 .
- Hack CE, Relan A, Baboeram A, et al., et al. Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IGE antibodies. Clin Drug Investig. 2013;33(4):275–281.
- ANNEX I. Summary of product characteristics. Ruconest 2100 U powder for solution for injection. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001223/WC500098542.pdf.
- Feussner A, Kalina U, Hofmann P, et al. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion. 2014;54(10):2566–2573.
- Lev Pharmaceuticals I. Cinryze (C1 esterase inhibitor [human]) package insert [Internet]. 2014. [cited 2015 Nov 20]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM129918.pdf.
- CSL Behring GmbH. Berinert (C1 esterase inhibitor [human]) package insert. 2014. [cited 2015 Nov 23]. Available from: http://www.fda.gov/downloads/%E2%80%A6/UCM186268.pdf
- Arzneimittelkommission der Deutschen Aertzteschaft. Schwerwiegende Thrombenbildung nach Berinert HS. Dtsch Aerztebl. 2000;97:B–864.
- Reshef A, Moldovan D, Obtulowicz K, et al., et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy. 2013;68(1):118–24.
- Farkas H, Kohalmi KV, Veszeli N, et al. Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema. Ann Allergy Asthma Immunol. 2015;114(1):64–65.
- Farkas H, Csuka D, Zotter Z, et al., et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J Allergy Clin Immunol. 2013;131(3):909–911.
- Czaller I, Visy B, Csuka D, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):44–49.
- Hakl R, Kuklinek P, Litzman J. Treatment of acute hereditary angioedema attacks with recombinant C1 inhibitor during pregnancy - a single case experience. Allergy. 2014;69:497.
- Bowen T, Cicardi M, Farkas H, et al., et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6(1):24.
- Craig T, Aygoren-Pursun E, Bork K, et al., et al. WAO guideline for the management of Hhereditary angioedema. World Allergy Organ J. 2012;5(12):182–99.
- Farkas H, Csuka D, Veszeli N, et al. Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Proc. 2014;35(3):255–9.
- Zanichelli A, Wu M, Cicardi M, et al. Treatment of hereditary angioedema with recombinant human C1 Inhibitor in a real-life setting: the experience of the HAE Centre in Milan. World Allergy Organ J. 2015;8(Suppl 1):A173.